Treating NSCLC metastases in the CNS with EGFR-tyrosine kinase inhibitors (TKIs) reduces CNS tumor progression more than cytotoxic chemotherapies and radiation therapies [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.